CLINICAL TRIALS PROFILE FOR POLIVY

All Clinical Trials for POLIVY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04231877 ↗	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Recruiting	Genentech, Inc.	Phase 1	2020-10-27	This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy for the treatment of patients with untreated large B-cell lymphoma that grows and spreads quickly and has severe symptoms (aggressive). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in combination chemotherapy such as etoposide, cyclophosphamide, and doxorubicin work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving polatuzumab vedotin in addition to etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab may help treat patients with aggressive large B-cell lymphoma.
NCT04231877 ↗	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Recruiting	National Cancer Institute (NCI)	Phase 1	2020-10-27	This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy for the treatment of patients with untreated large B-cell lymphoma that grows and spreads quickly and has severe symptoms (aggressive). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in combination chemotherapy such as etoposide, cyclophosphamide, and doxorubicin work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving polatuzumab vedotin in addition to etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab may help treat patients with aggressive large B-cell lymphoma.
NCT04231877 ↗	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Recruiting	University of Washington	Phase 1	2020-10-27	This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy for the treatment of patients with untreated large B-cell lymphoma that grows and spreads quickly and has severe symptoms (aggressive). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in combination chemotherapy such as etoposide, cyclophosphamide, and doxorubicin work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving polatuzumab vedotin in addition to etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab may help treat patients with aggressive large B-cell lymphoma.
NCT04659044 ↗	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Not yet recruiting	National Cancer Institute (NCI)	Phase 2	2021-12-31	This phase II trial studies the effect of polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cell growth. Rituximab hyaluronidase is a combination of rituximab and hyaluronidase. Rituximab binds to a molecule called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Hyaluronidase allows rituximab to be given by injection under the skin. Giving rituximab and hyaluronidase by injection under the skin is faster than giving rituximab alone by infusion into the blood. Giving polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human may work better than standard therapy in treating patients with mantle cell lymphoma.
NCT04659044 ↗	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Not yet recruiting	Academic and Community Cancer Research United	Phase 2	2021-12-31	This phase II trial studies the effect of polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cell growth. Rituximab hyaluronidase is a combination of rituximab and hyaluronidase. Rituximab binds to a molecule called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Hyaluronidase allows rituximab to be given by injection under the skin. Giving rituximab and hyaluronidase by injection under the skin is faster than giving rituximab alone by infusion into the blood. Giving polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human may work better than standard therapy in treating patients with mantle cell lymphoma.

Clinical Trial Conditions for POLIVY

Condition Name

Condition Name for POLIVY
Intervention	Trials
Recurrent Diffuse Large B-Cell Lymphoma	2
Refractory Diffuse Large B-Cell Lymphoma	2
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	2
Aggressive Non-Hodgkin Lymphoma	2

Condition MeSH

Condition MeSH for POLIVY
Intervention	Trials
Lymphoma	10
Lymphoma, B-Cell	7
Lymphoma, Non-Hodgkin	5
Lymphoma, Large B-Cell, Diffuse	4

Clinical Trial Locations for POLIVY

Trials by Country

Trials by Country for POLIVY
Location	Trials
United States	18
Czechia	1

Trials by US State

Trials by US State for POLIVY
Location	Trials
Washington	3
California	2
New York	2
Missouri	2
Oklahoma	1

Clinical Trial Progress for POLIVY

Clinical Trial Phase

Clinical Trial Phase for POLIVY
Clinical Trial Phase	Trials
Phase 2	9
Phase 1/Phase 2	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for POLIVY
Clinical Trial Phase	Trials
Not yet recruiting	8
Recruiting	4

Clinical Trial Sponsors for POLIVY

Sponsor Name

Sponsor Name for POLIVY
Sponsor	Trials
National Cancer Institute (NCI)	5
Genentech, Inc.	4
University of Washington	2

Sponsor Type

Sponsor Type for POLIVY
Sponsor	Trials
Other	11
Industry	5
NIH	5

Clinical Trials Update, Market Analysis, and Projection for POLIVY (polatuzumab vedotin-piiq)

Last updated: January 25, 2026

Summary

This report presents a comprehensive analysis of POLIVY (polatuzumab vedotin-piiq), a direct-acting antibody-drug conjugate (ADC) targeting CD79b for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including recent clinical trial developments, market dynamics, competitive landscape, and future forecasts. It consolidates latest data up to 2023, emphasizing regulatory milestones, trial outcomes, commercial potential, and strategic insights relevant to pharmaceutical stakeholders and investors.

---

What are the Latest Clinical Developments for POLIVY?

Overview of Clinical Trials for POLIVY

POLIVY (developed by Genentech/Roche) received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2019 for relapsed or refractory DLBCL when given in combination with bendamustine and rituximab (BR). The product has since undergone multiple high-impact trials to confirm efficacy, safety, and potential new indications.

Trial Phase	Trial Name / Number	Status	Key Outcomes	Completion Date
Phase II	GO29365 (NCT02257567)	Completed	ORR: 45% (intent-to-treat), CR: 40%, median duration of response: 9.5 months, manageable safety profile	2019
Phase III	POLARIX (NCT03274492)	Ongoing	Comparing POLIVY + R-CHP versus R-CHOP in untreated DLBCL; primary endpoint PFS; recruitment completed, results awaited	Estimated 2024-2025
Phase Ib/II	Various combination studies (e.g., with tafasitamab)	Ongoing	Exploring efficacy in other B-cell malignancies, including follicular lymphoma and primary CNS lymphoma	Ongoing

Regulatory Milestones and Approvals

• FDA Fast Track Designation: Granted in 2018 for relapsed/refractory DLBCL based on promising early-phase trial data.
• Accelerated Approval (2019): Approved for use in combination with bendamustine and rituximab in R/R DLBCL.
• Post-Approval Confirmatory Trials: Ongoing to verify long-term efficacy, safety, and label expansions.

Key Clinical Data and Efficacy

• Overall Response Rate (ORR): 45% in Phase II trials.
• Complete Response (CR): 40% in the same cohort.
• Median Duration of Response: 9.5 months.
• Adverse Events: Neutropenia, peripheral neuropathy, fatigue—manageable with dose adjustments.

---

Market Landscape and Competitive Positioning

Current Market Size and Segmentation

Parameter	Value	Source / Notes
Global B-cell Lymphoma Market (2023)	$4.9 billion	[1]
DLBCL Market Share (primary indication)	~70% of non-Hodgkin lymphoma	[2]
Relapsed/Refractory DLBCL Segment	~$2.3 billion	[3]
POLIVY's Current Market Share	Approx. 25-30% in R/R DLBCL	Estimated based on sales data [4]

Key Competitors

Drug/Product	Mechanism	Approval Status	Market Position	Notes
Polivy (POLIVY)	ADC targeting CD79b	Approved (2019)	First-in-class ADC for DLBCL	Market leader in R/R DLBCL
R-CHOP	Monotherapy (antibody + chemo)	Standard frontline	First-line treatment	Extensive clinical use
MabThera (Rituximab)	Anti-CD20 monoclonal antibody	Approved for R/R DLBCL	Companion or alternative	Competing with POLIVY in combination therapies
Trodelvy (sacituzumab govitecan)	ADC targeting Trop-2	Approved for metastatic triple-negative breast cancer	Potential competitor in CD-Targeted ADC space	Growing pipeline for hematologic malignancies

Market Dynamics and Growth Drivers

• Expansion of Indications: Ongoing trials targeting follicular lymphoma, primary CNS lymphoma, and combination regimens.
• Regulatory Progress: Potential approval for new indications could expand addressable market.
• Immuno-oncology Integration: Combining POLIVY with checkpoint inhibitors or CAR T-cell therapies.
• Pricing Strategy: Premium pricing (~$18,000 - $25,000 per treatment cycle) justified by clinical benefits and complex manufacturing.

Challenges and Risks

• Competition: Emergence of bispecific antibodies and CAR T-cell therapies, e.g., Breyanzi (lisocabtagene maraleucel), Tecartus (brexucabtagen autoleucel).
• Safety Profile: Peripheral neuropathy, cytopenias may limit long-term use.
• Manufacturing & Supply Chain: ADCs require complex production, impacting costs and scalability.
• Reimbursement & Market Access: Navigating payer policies remains critical for widespread adoption.

---

Market Projections and Future Outlook

Revenue Forecasting (2023-2030)

Year	Estimated Sales (USD Billion)	Growth Rate (%)	Notes
2023	$600 million	—	Initial post-approval sales
2024	$850 million	41.7%	Impact of POLARIX trial results, expanding indications
2025	$1.2 billion	41.2%	Regulatory submissions in new indications
2026	$1.6 billion	33.3%	Market penetration, competitive pressures
2027-2030	$2.2 - $3 billion	10-20% CAGR	Further expansion, indication approvals

Scenario Analysis

• Optimistic: Early approval in follicular lymphoma; combination with immunotherapies enhances sales.
• Moderate: Delays in Phase III results or safety concerns limit growth.
• Pessimistic: Competitive landscape shifts toward novel modalities, reducing market share.

Key Market Drivers

• Unmet medical needs in R/R DLBCL.
• Increasing adoption of ADCs and targeted therapies.
• Potential expansion via combination regimens.
• Favorable reimbursement environments.

---

Comparison with Similar Drugs

Parameter	POLIVY (Polatuzumab vedotin)	Tisagenlecleucel (Kymriah)	Breyanzi	Blincyto
Drug Type	ADC	CAR T-cell	CAR T-cell	Bi-specific T-cell engager
Indication	R/R DLBCL (approved); trials for other	R/R ALL, DLBCL	R/R DLBCL, follicular lymphoma	ALL, lymphoma
Approval Year	2019	2017	2021	2014
Estimated Sales (2023)	$600M	~$900M	~$650M	~$750M
Line of Therapy	Second-line (approved combo)	Second/third-line	Second-line in some indications	First-line (some indications)

---

Key Regulatory and Policy Trends

Policy / Trend	Impact on POLIVY	Source / Authority
Accelerated approvals & breakthroughs	Faster market entry, revenue potential	FDA, EMA
Payer reimbursement policies	Access and affordability considerations	CMS, private payers
Orphan /rare disease incentives	Not applicable for DLBCL, but relevant for expansion	FDA, EMA
Data-sharing and transparency mandates	Enhance credibility, facilitate trials	FDA, EMA, ICH

---

FAQs

1. What are the current clinical trial statuses for POLIVY?

POLIVY's pivotal trial, POLARIX (NCT03274492), is ongoing with primary endpoint data expected by 2024-2025. Additional trials assess its combination with other agents in follicular lymphoma and CNS lymphomas, with some phase Ib/II studies completed or ongoing.

2. How does POLIVY compare to other treatments for R/R DLBCL?

POLIVY offers a targeted approach with a favorable safety profile compared to traditional chemotherapies. It is among the first ADCs approved specifically for R/R DLBCL. Its market position is reinforced by its efficacy demonstrated in phase II trials, though CAR T-cell therapies like Yescarta and Breyanzi are also approved, particularly for patients eligible for cellular therapy.

3. What is the future outlook for POLIVY’s market expansion?

Potential expansion through regulatory approval in frontline settings, new indications like follicular lymphoma, and combination regimens could double or triple its addressable market by 2030. Pending positive trial outcomes and favorable reimbursement strategies are critical.

4. What are key challenges influencing POLIVY's market growth?

Competitive advances in cell therapies, bispecific antibodies, and emerging ADCs, alongside manufacturing complexities and safety management, pose significant hurdles. Market penetration depends on demonstrating superior efficacy, safety, and cost-effectiveness.

5. How will pricing influence POLIVY’s adoption?

High treatment costs (~$20,000 per cycle) require strong clinical benefit demonstrations for reimbursement. Payer negotiations and value-based pricing strategies remain essential to maximize market access.

---

Key Takeaways

• Clinical evidence supports POLIVY’s efficacy in R/R DLBCL with manageable safety, underpinning its approved and expanding indications.
• Regulatory momentum—including ongoing Phase III trials—may lead to broadening its therapeutic scope, particularly in untreated or other relapsed lymphomas.
• Market potential remains substantial but is challenged by competing therapies, notably CAR T-cells and bispecific antibodies.
• Forecasted revenues could exceed $2 billion globally by 2027, contingent on successful trial outcomes and regulatory approvals.
• Strategic positioning through combination therapies and indication expansion can enhance competitiveness and market share.

---

References

1. MarketResearch.com, "Global Non-Hodgkin Lymphoma Market," 2023.
2. IQVIA, "Hematalogy & Oncology Market Trends," 2022.
3. FDA, “FDA approvals and press releases,” 2019-2023.
4. Company financial disclosures, Roche/Genentech, 2023.